iShares Biotechnology ETF (NASDAQ:IBB) Reaches New 52-Week High at $150.24

iShares Biotechnology ETF (NASDAQ:IBB)’s share price reached a new 52-week high on Thursday . The stock traded as high as $150.24 and last traded at $149.17, with a volume of 99680 shares traded. The stock had previously closed at $147.52.

iShares Biotechnology ETF Price Performance

The firm’s 50 day simple moving average is $145.80 and its two-hundred day simple moving average is $138.61.

Institutional Trading of iShares Biotechnology ETF

Hedge funds have recently added to or reduced their stakes in the business. Future Financial Wealth Managment LLC bought a new position in shares of iShares Biotechnology ETF during the first quarter valued at about $27,000. Bbjs Financial Advisors LLC bought a new position in shares of iShares Biotechnology ETF during the second quarter valued at about $31,000. Pacifica Partners Inc. raised its stake in shares of iShares Biotechnology ETF by 118.2% during the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock valued at $33,000 after acquiring an additional 130 shares during the last quarter. YHB Investment Advisors Inc. bought a new position in shares of iShares Biotechnology ETF during the first quarter valued at about $37,000. Finally, Mather Group LLC. bought a new position in shares of iShares Biotechnology ETF during the first quarter valued at about $57,000. 62.45% of the stock is owned by institutional investors.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.